Publications
Aggarwal R, Bhatt DL, Miller M, Ballantyne CM, Brinton EA, Jacobson TA, Ketchum SB, Tardif JC, Budoff MJ, Figtree GA, Steg PG, REDUCE-IT Investigators. Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT. American journal of preventive cardiology. 2026. PMID: 42006413
Han Y, Byun J, VanLith CJ, Cooley MA, Shaw VR, Hatia RI, Ahmed FY, Giama NH, Ali HM, Campbell NA, Hassan M, Andersen JB, Ankoma-Sey V, Banales JM, Bujanda L, Bathe OF, Bekaii-Saab TS, Borad MJ, Björkström NK, Chan CHF, Cleary SP, Cornillet M, Folseraas T, Galle PR, Genkinger JM, MacInnis RJ, Gores GJ, Goyal L, Houlston RS, Ilyas SI, Javle M, Johansen JS, Christensen TD, Kamath AS, Kelley RK, Khan SA, Kim RD, Kwee SA, Lamarca A, Lammert F, LaRusso NF, Lindsey S, Macias RIR, Malhi H, Patel TC, Permuth JB, Reeves HL, Rossi S, Sanchez W, Smoot RL, Swerdlow AJ, Tran Cao HS, Valle JW, Weinmann A, Weinmann-Menke J, Wong LL, Zhang X, Zimmer V, Zhu AX, Lazaridis KN, Juran BD, Jalal P, Knox JJ, Hutchinson A, Hicks B, Koshiol JE, Chanock SJ, Hassan MM, Amos CI, McGlynn KA, Roberts LR. Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. Hepatology (Baltimore, Md.). 2026. PMID: 41627892
Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly ME, Frosch Z, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Hoppe RT, Isufi I, Johnston PB, Kelly K, Kenkre VP, Kline J, Lynch RC, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter JN, Yahalom J, Yang JC, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41671432
Ma S, Spinner MA. Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41698326
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for immunotherapy of cancer. 2026. PMID: 41617393
Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, André F, Im SA, Goncalves MD, Lacouture ME, Fasching PA, Leung R. Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. ESMO open. 2026. PMID: 41604817
Martin TG, van de Donk NWCJ, Rodríguez-Otero P, Mateos MV, Kobos R, Chastain K, Doyle M, Nooka AK. Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma. Future oncology (London, England). 2026. PMID: 41574880
Foisey MG, Garcia J, Li X, Yang X, Hilburger C, Thienpont C, Chaves-Martinez A, Belkaya S, Truong T, Zhu I, Liu R, Hyrenius-Wittsten A, Almeida R, Shy BR, Allen GM, Wyman S, Roybal KT. Synthetic Hybrid Receptors for Safer and Programmable T Cell Therapy. bioRxiv : the preprint server for biology. 2026. PMID: 41648153
Luck C, Luo Y, Vasileva E, Jacobs KA, Riad J, Macaraig CD, Ponce RKM, Amatruda JF, Okimoto RA. Modeling of Capicua Family Fusion Oncoprotein-Driven Cancers Reveals Gene-Specific Functionality. Molecular cancer research : MCR. 2026. PMID: 41575738
Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41569419
Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41569419
Herasymenko O, Silva M, Correy GJ, Abu-Saleh AAA, Ackloo S, Arrowsmith C, Ashworth A, Ban F, Beck H, Bishop KP, Bohórquez HJ, Bolotokova A, Breznik M, Chau I, Chen Y, Cherkasov A, Dehaen W, Della Corte D, Denzinger K, Doering NP, Edfeldt K, Edwards A, Fayne D, Gentile F, Gibson E, Gokdemir O, Gunnarsson A, Günther J, Irwin JJ, Jensen JH, Harding RJ, Hillisch A, Hoffer L, Hogner A, Hutchinson A, Kandwal S, Karlova A, Koirala K, Kotelnikov S, Kozakov D, Lee J, Lee S, Lessel U, Liu S, Liu X, Loppnau P, Meiler J, Moretti R, Moroz YS, Muvva C, Oprea TI, Paige B, Pandit A, Park K, Poda G, Protopopov MV, Pütter V, Ravichandran R, Rognan D, Rosta E, Sabnis Y, Scott T, Seitova A, Sharma P, Sindt F, Song M, Steinmann C, Stevens R, Talagayev V, Tararina VV, Tarkhanova O, Tingey D, Trant JF, Treleaven D, Tropsha A, Walters P, Wells J, Westermaier Y, Wolber G, Wortmann L, Zheng S, Fraser JS, Schapira M. CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2. Journal of chemical information and modeling. 2026. PMID: 41565251
Pan S, Fernández-Maestre I, Chang KC, Van Haver S, Wereski MG, Haugh AM, Tsai KK, Daud AI, Bowman RL, Vasudevan HN, Levine RL, Abate AR. PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells. Nature communications. 2026. PMID: 41565684
Pan S, Fernández-Maestre I, Chang KC, Van Haver S, Wereski MG, Haugh AM, Tsai KK, Daud AI, Bowman RL, Vasudevan HN, Levine RL, Abate AR. PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells. Nature communications. 2026. PMID: 41565684
Li T, Ilano A, Arias-Badia M, Luong D, Chang H, Kwek SS, Allaire K, Chumber A, Sakamoto M, Clark M, Lea A, Bridge M, Chen B, Liu E, Porten S, Meng MV, Erlich LIR, Oh DY, Fong L. Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cells. Proceedings of the National Academy of Sciences of the United States of America. 2026. PMID: 41557789
Li T, Ilano A, Arias-Badia M, Luong D, Chang H, Kwek SS, Allaire K, Chumber A, Sakamoto M, Clark M, Lea A, Bridge M, Chen B, Liu E, Porten S, Meng MV, Erlich LIR, Oh DY, Fong L. Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cells. Proceedings of the National Academy of Sciences of the United States of America. 2026. PMID: 41557789
Tolaney SM, Sammons S, Sandoval-Leon A, Cortes J, Liepa AM, Grimes BR, He D, Cui ZL, Roose J, Gathirua-Mwangi W, Moreira K, O'Shaughnessy J, Neven P, Johnston SRD, Rugo HS. Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data. ESMO open. 2026. PMID: 41558202
Hertz DL, Venook AP. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41632507
Tsui M, Hu K, Song H, Hsu SC, Chen YA, Nuniz L, Pham JH, Chang CH, Hui KSF, Quigley DA, Li J, Huang FW. Landscape of allele-specific expression in prostate cancer reveals recurrent, stage-specific events in AR signaling and resistance pathways. Molecular cancer research : MCR. 2026. PMID: 41543497
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772